| Bioactivity | Oblimersen sodium is a BCL-2 inhibitor targeting BCL-2 RNA. Oblimersen sodium specifically binds to the first six codons of the bcl-2 mRNA sequence, resulting in degradation of bcl-2 mRNA and induces apoptosis by down-regulating expression of Bcl-2. Oblimersen sodium can be used for cancer research[1][2][3]. |
| Name | Oblimersen sodium |
| Formula | C172H204N62Na17O91P17S17 |
| Molar Mass | 6058.28 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Loriot Y, et, al. Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response. Anticancer Res. 2010 Oct;30(10):3869-78. [2]. Hu Y, et, al. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer. Clin Cancer Res. 2004 Nov 15;10(22):7662-70. [3]. Klasa RJ, et, al. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):193-213. |
Oblimersen sodium
CAS: F: C172H204N62Na17O91P17S17 W: 6058.28
Oblimersen sodium is a BCL-2 inhibitor targeting BCL-2 RNA. Oblimersen sodium specifically binds to the first six codons
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.